FDA accepts Iroko lower dose submicron diclofenac NDA for review
According to the firm, the lower dose submicron diclofenac NDA submission included data from a study conducted on 428 healthy adults in a Phase 3 multi-center, randomized process,
Faeth Therapeutics has received the US Food and Drug Administration’s (FDA) fast track designation for the sapanisertib and serabelisib (PIKTOR) with paclitaxel combination to treat advanced or recurrent endometrial cancer.